HC Wainwright Issues Pessimistic Forecast for SCPH Earnings

scPharmaceuticals Inc. (NASDAQ:SCPH) – Equities researchers at HC Wainwright reduced their FY2024 earnings per share estimates for shares of scPharmaceuticals in a note issued to investors on Thursday, November 14th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($1.43) per share for the year, down from their prior forecast of ($1.33). HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.37) per share. HC Wainwright also issued estimates for scPharmaceuticals’ Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.19) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.45 EPS.

Separately, Craig Hallum reduced their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th.

scPharmaceuticals Stock Down 3.2 %

Shares of NASDAQ:SCPH opened at $3.35 on Monday. The company has a quick ratio of 3.66, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The company has a market capitalization of $167.63 million, a P/E ratio of -1.77 and a beta of 0.15. scPharmaceuticals has a 52-week low of $3.08 and a 52-week high of $6.71. The stock’s fifty day simple moving average is $4.46 and its 200-day simple moving average is $4.48.

Institutional Investors Weigh In On scPharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Suvretta Capital Management LLC acquired a new stake in scPharmaceuticals in the 3rd quarter worth about $9,343,000. Rubric Capital Management LP increased its stake in shares of scPharmaceuticals by 35.5% during the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after acquiring an additional 1,250,000 shares during the last quarter. King Luther Capital Management Corp lifted its holdings in shares of scPharmaceuticals by 51.8% during the 2nd quarter. King Luther Capital Management Corp now owns 2,205,140 shares of the company’s stock worth $9,592,000 after acquiring an additional 752,005 shares during the period. Stonepine Capital Management LLC boosted its position in shares of scPharmaceuticals by 84.7% in the third quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock worth $3,552,000 after acquiring an additional 357,171 shares during the last quarter. Finally, Bank of Montreal Can purchased a new stake in scPharmaceuticals in the second quarter valued at approximately $1,544,000. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.